-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:
LLY delivered exceptional Q1 results with non-GAAP EPS of $8.55 (+156% Y/Y), $1.56 above consensus, and revenue of $19.8B (+56%), $2M above estimates. The GLP-1 franchise drove performance with combined Mounjaro and Zepbound sales reaching ~$12.8B, representing 65% of total revenue, with Mounjaro achieving $8.7B (+125%) and Zepbound $4.2B (+80%). We view the continued GLP-1 momentum, strong international expansion including China NRDL inclusion, and FDA approval of the Foundayo oral pill as key catalysts supporting our investment thesis. Management raised 2026 guidance to $82B-$85B revenue and $35.50-$37.00 non-GAAP EPS, demonstrating confidence in sustained solid growth. The company accelerated strategic capital deployment with four proposed acquisitions in Q1, including Orna Therapeutics and Kelonia Therapeutics, while increasing R&D investment 28% to $3.5B, reflecting commitment to pipeline diversification across oncology and next-generation therapeutics, in our view.